649TiP PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer

After radical prostatectomy, 25% to 35% of patients develop progression of serum prostate-specific antigen (PSA). Positron emission tomography of radiolabelled prostate-specific membrane antigen ligands (PSMA-PET) is more sensitive and specific than conventional imaging for lesion detection. This trial-in-progress (NCT04557059) uses PSMA-PET-evaluated staging and outcomes to investigate adding apalutamide (a next-generation nonsteroidal androgen...